Market Intelligence, Clinical Progress, and High-Purity Reagents for Atopic Dermatitis, Asthma, Type 2 Inflammation, and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-13 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-13 Wild-Type & Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View IL-13 Products |
| Gene Delivery | IL-13 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL-13 Products |
| Benchmark Ab | Anti-IL-13 (Sequence of Lebrikizumab / Tralokinumab) Recombinant positive control for competitive binding assays. |
View IL-13 Products |
| Validator | IL-13 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View IL-13 Products |
| Related Target A | IL-4Ra Shared receptor subunit for IL-4 and IL-13 signaling; crucial for dual-pathway blockade. |
View IL-4Ra Products |
| Related Target B | IL-13Ra1 Primary receptor mediating IL-13 signaling; essential for competitive binding assays. |
View IL-13Ra1 Products |
| Related Target C | TSLP Upstream master regulator of Type 2 inflammation; combination therapy target. |
View TSLP Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse/Human Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity and Theoretical MW strictly verified. |
| Epitope Binning & Receptor Interference | High-purity IL-13Ra1 and IL-13Ra2 proteins available to map competitive binding (e.g., blocking IL-4Ra recruitment). |
| IL-4 vs. IL-13 Selectivity Screening | Purified Human IL-13 and IL-4 proteins available as homolog panel; Sequence-verified distinct epitopes for cross-reactivity assessment. |
| Receptor Competition Assay | IL-13Rα1 and IL-4Rα recombinant extracellular domains (ECD-Fc) available for SPR/BLI binding studies. |
| Neutralizing Potency Validation | Clinical benchmark antibodies (Lebrikizumab, Tralokinumab sequences) included as assay controls. |
| False Positive Elimination | Validated IL-13 siRNA included for target specificity confirmation in functional assays. |
Live IL-13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-13 therapeutics is intensifying, with major players shifting focus from broad immunosuppression to precise Type 2 cytokine blockade. As first-generation IL-13 specific antibodies (Lebrikizumab, Tralokinumab) and dual IL-4/IL-13 blockers (Dupilumab via IL-4Rα) establish dominance in atopic dermatitis, the next wave of R&D is targeting fibrotic diseases (IPF, SSc) and exploring upstream inhibition combinations with TSLP and IL-5. The next wave also includes decoupled signaling pathways, extending dosing intervals via ultra-high affinity binding, and addressing severe, localized inflammatory conditions like eosinophilic esophagitis (EoE) and prurigo nodularis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Anti-IL-13 | Eli Lilly (Lebrikizumab), Leo Pharma (Tralokinumab) | Atopic Dermatitis, Asthma | High-affinity neutralization validation; IL-4 selectivity panel. |
| Dual IL-4/IL-13 Blockade | Regeneron/Sanofi (Dupilumab) | AD, Asthma, CRSwNP | IL-4Rα/IL-13 competition assays; Cross-reactive Ab screening. |
| Bispecific Antibody | Sanofi, Regeneron, Emerging Biotech | Severe Asthma, COPD | Selectivity Assay (Need Cross-reactive Abs & Cytokine Panels) |
| Small Molecule / Peptide | Various Biotechs | Topical/Dermatological, Pulmonary Fibrosis | Binding Interference (Need Endotoxin Controlled Recombinant Proteins) |